RheaVita
RheaVita is a Belgian pharmaceutical technology company developing continuous freeze-drying (lyophilization) equipment and process services for biologic drug manufacturers and CDMOs, using its proprietary RheaLyo platform with spin-freezing, infrared heating, and real-time PAT monitoring.
- Company typePrivate
- Founded2018
- HeadquartersGhent, Belgium
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What RheaVita does
RheaVita is a Belgian pharmaceutical technology company founded in 2018 and headquartered in Ghent, Belgium. It develops and commercializes continuous freeze-drying (lyophilization) equipment and process services for biologic, vaccine, and injectable drug manufacturers, with a customer base spanning large pharmaceutical companies (Sanofi, Pfizer, Bayer, GSK) and CDMOs/specialty service providers (Patheon/Thermo Fisher, Coriolis Pharma). The company's stated mission is to replace traditional batch lyophilization with a continuous, single-vial process that reduces cycle time and improves consistency for thermo-sensitive drug products.
The core platform, branded RheaLyo, combines spin-freezing, infrared heating, and real-time Process Analytical Technology (PAT) monitoring with computer-vision-based visual inspection and closed-loop process control. RheaVita offers a staged product line: the RheaLyo Mono system (R&D scale, with a BSL-2 compliant variant for biosafety-handled products), the RheaLyo Multi system (pre-clinical), and the GMP-Flex line for commercial cGMP manufacturing. The technology is protected by granted patents WO2013036107 and WO2018033468, with additional applications pending, and the company is engaged with FDA and EMA on the regulatory pathway for continuous lyophilization.
RheaVita's business model is a hybrid of capital equipment sales and process services. Equipment revenue is generated through direct sales to pharma and CDMO customers in Europe and the US and through distribution partners in Japan, Korea, and India. Service revenue comes from feasibility studies, stability batch production, and the Continuous Lyo Academy training program, which also functions as a market-development channel. Strategic OEM integration with IMA Life (2023) and CDMO adoption by Patheon/Thermo Fisher (2024-2025) are the principal go-to-market vehicles beyond direct sales. The company is backed by Novalis Biotech Acceleration and PMV following a EUR 2.5M Series A in June 2021.
RheaVita firmographics
Firmographics- Name
- RheaVita
- Legal name
- RheaVita
- Website
- https://rheavita.com
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- RheaVita is a Belgian pharmaceutical technology company developing continuous freeze-drying (lyophilization) equipment and process services for biologic drug manufacturers and CDMOs, using its proprietary RheaLyo platform with spin-freezing, infrared heating, and real-time PAT monitoring.
- Ownership category
- akta.pro rank
RheaVita industry classification
Industry- Product category
- Pharmaceutical Lyophilization Equipment
- SIC
- Special Industry Machinery, Nec (3559)
- akta.pro primary industry
- Aseptic Processing, Fill-Finish & Sterile Manufacturing Tech (isolators, lyophilization interfaces) (HLAAAJAG)
- akta.pro secondary industries
- Lyophilization (Freeze-Drying) CDMO (HLAGABAI), Fill-Finish & Aseptic Drug Product Manufacturing (Biologics/ATMP) (HLAGAGAG)
Keywords
Where RheaVita is headquartered
LocationHeadquarters
- HQ city
- Ghent
- HQ country
- Belgium
- HQ region
- Europe
Offices1 record
Markets served
RheaVita business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations, Infrastructure
Revenue model
- R&D Equipment Sales: Sale of RheaLyo Mono and RheaLyo Multi freeze-dryers for laboratory and pre-clinical use. Mono is single-vial unit for formulation development; Multi is larger version for stability batches with ~100 vials/day throughput.
- GMP Equipment Sales: Sale of GMP-Flex freeze-dryers for clinical and commercial production. Only commercial GMP-compliant continuous freeze-drying system available, covering 100K to 2M vials annually. Pre-engineering studies offered for facility implementation planning.
- Feasibility Studies: RheaVita conducts feasibility studies demonstrating RheaLyo technology compatibility with customer formulations. Charged by day fee. No CAPEX investment required from customers.
- Stability Batch Production: Outsource R&D freeze-drying using GMP-Flex 250 equipment operating under non-GMP conditions. Customers avoid CAPEX investment and staff training while receiving high-quality samples.
- Continuous Lyo Academy Training: Training courses on freeze-drying fundamentals and advanced continuous spin freeze-drying technology. Courses held at RheaVita facilities or customer site. Free webinars also offered.
- Lyo Recipe Development Services: Process development and optimization services for customer formulations. Expert services charged by day fee with customized quotes.
- Formulation Development Services: Full formulation development support for vaccines and biopharmaceuticals optimized for RheaLyo continuous freeze-drying process.
Go-to-market motion2 records
Distribution channels2 records
Marketing channels7 records
RheaVita product offering
Product offeringCore offering
RheaVita develops, manufactures, and sells continuous freeze-drying (lyophilization) equipment for biopharmaceutical products based on its proprietary RheaLyo spin-freezing technology. The company offers a scalable portfolio of R&D freeze-dryers (RheaLyo Mono, RheaLyo Multi), GMP-compliant production lines (GMP-Flex series covering 100K–2M vials annually), and BSL-2 compliant variants, complemented by professional services including feasibility studies, contract stability batch production, formulation and recipe development, and training through the Continuous Lyo Academy.
Product overview
RheaVita offers a scalable portfolio of continuous freeze-drying products centered on the RheaLyo™ technology platform. The RheaLyo™ Mono serves as the R&D cornerstone for rapid formulation and process development using single-vial units. The RheaLyo™ Multi is the larger pre-clinical version for stability batch production. The GMP-Flex lines represent the only commercial GMP-compliant continuous freeze-drying systems for clinical and commercial production, available in multiple capacity configurations (4/120, 16/240, 24/600). A BSL-2 compliant variant of the Mono is available for handling hazardous biological samples. All products share the core spin-freezing and infrared drying technology with PAT-enabled individual vial control, enabling direct scale-out from R&D to GMP with minimal tech transfer. Beyond equipment sales, RheaVita provides CDMO services including feasibility studies, stability batch production, and Continuous Lyo Academy training.
Differentiator
Problem solved
Functional benefit
Brands
- RheaLyo™: Brand name for RheaVita's continuous freeze-drying technology platform, including RheaLyo Mono, RheaLyo Multi, and GMP-Flex product lines.
- Continuous Lyo Academy
Products and services
- RheaLyo Mono Freeze-Dryer R&D freeze-dryer for rapid formulation and process development. Single-vial unit enables ultra-fast continuous freeze-drying (hours instead of days) with minimal sample use. Designed for biopharmaceutical and formulation development scientists. Processes can be directly scaled to GMP production through the scale-out principle.
- RheaLyo Multi Freeze-Dryer Pre-clinical freeze-dryer designed for stability batch production. Features throughput of approximately 100 vials per day. Seamlessly scales from RheaLyo Mono recipes with minimal tech transfer to GMP production. Targeted at biopharma development teams needing larger stability batches than the Mono provides.
- RheaLyo GMP-Flex Lines GMP-compliant continuous freeze-drying system for clinical and commercial pharmaceutical production. Multiple configurations (4/120, 16/240, 24/600) covering 100,000 to 2 million vials annually. Features robotic automation in isolator conditions, CIP and SIP procedures, non-viable and viable particle monitoring, and documentation systems aligned with regulatory requirements. The only commercial GMP-compliant continuous freeze-drying system available.
- BSL-2 Compliant RheaLyo Mono Freeze-Dryer Specialized BSL-2 compliant variant of the RheaLyo Mono freeze-dryer for handling infectious biological materials. Features dedicated biosafety cabinet, HEPA-14 filtration (0.2 μm), ULPA filter on vacuum pump (0.1 μm), vertical laminar flow through HEPA filter, and compliance with EN 12469 biosafety standards. Add-on module for existing RheaLyo Mono systems.
- Feasibility Studies Service where RheaVita conducts feasibility studies demonstrating RheaLyo technology compatibility with customer formulations. Charged by day fee with no CAPEX investment required from customers. Enables biopharma companies to evaluate continuous freeze-drying compatibility before committing to equipment purchases.
- Stability Batch Production Outsourced R&D freeze-drying service using GMP-Flex 250 equipment operating under non-GMP conditions. Customers avoid CAPEX investment and staff training while receiving high-quality stability batch samples. Targeted at biopharma companies needing stability data without capital investment.
- Continuous Lyo Academy Training Training courses on freeze-drying fundamentals and advanced continuous spin freeze-drying technology. Courses held at RheaVita facilities or customer site. Free webinars also offered online. Targeted at process engineers, formulation scientists, and operators in biopharmaceutical companies and CDMOs.
- Lyo Recipe Development and Formulation Development Services Process development, optimization, and full formulation development services for customer biopharmaceutical formulations. Expert services charged by day fee with customized quotes. Targeted at biopharma companies developing vaccines, monoclonal antibodies, recombinant proteins, LNPs, AAVs, and peptides for continuous freeze-drying on RheaLyo systems.
Quantifiable outcome
- Drying time reduced by up to 40x (hours instead of days)
- +5 more outcomes
Companies that use RheaVita
Customer profileNamed customers6 records
Segments3 records
Ideal customer profiles3 records
RheaVita technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability4 records
Feature7 records
RheaVita partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered flagship, minor and core.
- Patheon (Thermo Fisher Scientific)flagshipPatheon Monza site installed RheaLyo Mono freeze-dryer as part of expansion of biopharma capabilities. Monza facility handles LNP formulation development, analytical services, and production of monoclonal antibodies and recombinant proteins. RheaVita technology integrated with Patheon's Pharmaceutical Development Services.
- IMA LifeflagshipStrategic partnership to drive further technological development and commercial growth. IMA Life is a global provider of advanced aseptic pharmaceutical process and production solutions. Partnership announced with launch of BSL-2 compliant RheaLyo Mono freeze-dryer. IMA Life brings pharmaceutical equipment expertise and global commercial reach.
- LyoHUBminorRheaVita became formal member of LyoHUB, the Advanced Lyophilization Technology Hub. LyoHUB aims to advance science and technology of freeze-drying, identify best practices, conduct applied research, and disseminate knowledge. Membership aligns with RheaVita's continuous freeze-drying innovation.
- Ghent UniversitycoreFounding process concept originated from collaboration between RheaVita co-founders at Ghent University starting 2012. University provided research support for initial prototype development in 2018. Multiple PhDs and researchers from university have joined RheaVita team.
- CEPIminorCollaborative relationship mentioned in context of RheaVita's commitment to advancing lyophilization science alongside partnerships with Ghent University and others.
- Reifycsanalytical Co., Ltd.coreRegional distributor for Japan market. Located in Osaka (Wakasugi building, Naktsu 1-18-18, Kita-ku). Handles sales and support of RheaVita products in Japan.
- Hahnson ImpexcoreRegional distributor for Korea market. Located in Seoul (Suite 402, Seodu Bldg, 25 Baumoe-ro 20-gil, Seocho-Gu). Handles sales and support of RheaVita products in Korea.
- Automed Systems P LtdcoreRegional distributor for India market. Located in Bangalore (9B, KIADB Electronic City Phase 2). Handles sales and support of RheaVita products in India.
Scale indicators4 records
Recent moves7 records
Expansion highlights5 records
RheaVita competitors and assessment
Company assessmentBroad incumbents
- IMA Life: Global aseptic processing and pharmaceutical equipment leader, parent of Telstar, with a broad freeze-drying and fill-finish portfolio. Both RheaVita's flagship strategic partner and a potential competitor-developer of continuous lyophilization technology.
- GEA Group: Major incumbent manufacturer of GMP lyophilization systems with deep installed base in pharma. Competes head-to-head with RheaVita's GMP-Flex lines for biopharma freeze-drying equipment budgets.
- SPX Technologies (formerly SPX FLOW): Established pharmaceutical processing equipment provider with freeze-drying capabilities, serving large biopharma manufacturers globally. Overlaps with RheaVita in aseptic fill-finish and lyophilization equipment.
- Tofflon Science and Technology: Chinese-headquartered manufacturer of pharmaceutical equipment including freeze-dryers, aseptic filling lines, and isolators. Targets the same biopharma lyophilization equipment market as RheaVita with a broader portfolio.
- Optima Pharma: German specialist in aseptic filling, closing, and freeze-drying systems for pharma and biotech. Provides GMP-compliant lyophilization equipment directly competing with RheaVita's GMP-Flex lines.
Direct peers
- HOF Sonderanlagenbau: German engineering firm specializing in freeze-drying and lyophilization technology for pharmaceuticals, including continuous solutions. Direct competitor in continuous lyophilization development.
Emerging players
- Aseptic Technologies (AAT Bioquest): Specialist in closed-vial and aseptic fill-finish technology for injectable biologics. Adjacent competitor in the aseptic processing ecosystem relevant to RheaVita's freeze-drying customers.
Others
- Coriolis Pharma: Biologics formulation development CDMO that has integrated RheaVita's SVU technology. Functions as both customer and ecosystem partner in the continuous lyophilization space.
- Recipharm: Large CDMO offering lyophilization services across its manufacturing network. Represents both a potential customer for RheaLyo equipment and a downstream CDMO peer expanding into advanced biologics.
- BioLife Solutions: Provider of biopreservation and cold-chain solutions for cell and gene therapies. Adjacent to RheaVita's lyophilization offering in preserving high-value biologics and ATMPs.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
RheaVita social profiles
Digital presenceRheaVita compliance and trust
Trust signalCompliance3 records
RheaVita financial estimates
Financial estimateRevenue estimate
Valuation estimate
RheaVita leadership team
Management profileNumber of profiles
Profiles11 records
RheaVita funding detail
Funding detailFunding overview
Funding rounds1 record
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
RheaVita M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about RheaVita
What does RheaVita do?
RheaVita develops, manufactures, and sells continuous freeze-drying (lyophilization) equipment for biopharmaceutical products based on its proprietary RheaLyo spin-freezing technology. The company offers a scalable portfolio of R&D freeze-dryers (RheaLyo Mono, RheaLyo Multi), GMP-compliant production lines (GMP-Flex series covering 100K–2M vials annually), and BSL-2 compliant variants, complemented by professional services including feasibility studies, contract stability batch production, formulation and recipe development, and training through the Continuous Lyo Academy.
Is RheaVita a public or private company?
RheaVita is a private company. It is classified as venture growth investor backed and is currently operating.
When was RheaVita founded?
RheaVita was founded in 2018. It employs 11 to 50 people.
Where is RheaVita based?
RheaVita is headquartered in Ghent, Belgium, in the Europe region.
How does RheaVita make money?
Seven revenue lines are on record. R&D Equipment Sales are the primary driver. The others are GMP Equipment Sales, feasibility Studies, stability Batch Production, continuous Lyo Academy Training, lyo Recipe Development Services and formulation Development Services.
Who are RheaVita's main competitors?
Broad incumbents on record are IMA Life, GEA Group, SPX Technologies (formerly SPX FLOW), Tofflon Science and Technology and Optima Pharma. HOF Sonderanlagenbau is listed as a direct peer. Aseptic Technologies (AAT Bioquest) is listed as an emerging player. Others are Coriolis Pharma, Recipharm and BioLife Solutions.
Does RheaVita have an API?
No public API is recorded for RheaVita.
What industry is RheaVita in?
RheaVita's product category is Pharmaceutical Lyophilization Equipment. Its primary akta.pro industry code is HLAAAJAG, Aseptic Processing, Fill-Finish & Sterile Manufacturing Tech (isolators, lyophilization interfaces), with a secondary code of HLAGABAI, Lyophilization (Freeze-Drying) CDMO. Its SIC code is 3559.